KEY FACTS
Terminology
Clinical Implications
TERMINOLOGY
Definitions
- Optison
- US contrast agent manufactured by GE Healthcare AS, Oslo, Norway
CLINICAL IMPLICATIONS
Dosage and Administration
CONTRAINDICATIONS
PRECAUTIONS
USE IN SPECIFIC POPULATIONS
Selected References
- Back SJ et al: Pediatric contrast-enhanced ultrasound in the United States: a survey by the Contrast-Enhanced Ultrasound Task Force of the Society for Pediatric Radiology. Pediatr Radiol. 48(6):852-857, 2018
- Eisenbrey JR et al: Contrast-enhanced subharmonic and harmonic ultrasound of renal masses undergoing percutaneous cryoablation. Acad Radiol. 22(7):820-6, 2015
- Wei K et al: The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr. 21(11):1202-6, 2008
- Strobel D et al: Phase inversion harmonic imaging versus contrast-enhanced power Doppler sonography for the characterization of focal liver lesions. Int J Colorectal Dis. 18(1):63-72, 2003
- Shi WT et al: Ultrasonic characterization of the nonlinear properties of contrast microbubbles. Ultrasound Med Biol. 26(1):93-104, 2000
- Brown JM et al: Contrast-enhanced ultrasound for guidance of local tumor ablation. Ultrasound Med Biol. 25(8):1213-9, 1999
- Barnhart J et al: Characteristics of Albunex: air-filled albumin microspheres for echocardiography contrast enhancement. Invest Radiol. 25 Suppl 1:S162-4, 1990
- Feinstein SB et al: Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J Am Coll Cardiol. 16(2):316-24, 1990
- Keller MW et al: Albunex: a safe and effective commercially produced agent for myocardial contrast echocardiography. J Am Soc Echocardiogr. 2(1):48-52, 1989
- Optison Product Insert. http://www3.gehealthcare.com/~/media/documents/MarketoPDFsnogating/OPT-1H-OSLO_Optison_BK. Accessed November 2018.
Related Differential Diagnoses
Loading...